Development of dyskinesias in a 5‐year trial of ropinirole and L‐dopa
Identifieur interne : 002852 ( Main/Exploration ); précédent : 002851; suivant : 002853Development of dyskinesias in a 5‐year trial of ropinirole and L‐dopa
Auteurs : Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Amos D. Korczyn [Israël] ; Peter P. De Deyn [Belgique] ; Carl E. Clarke [Royaume-Uni] ; Anthony E. Lang [Canada] ; Mona Abdalla [Royaume-Uni]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-11.
Descripteurs français
- Pascal (Inist)
English descriptors
- KwdEn :
Abstract
A 5‐year trial of ropinirole and levodopa in early Parkinson's disease showed that ropinirole is associated with reduced incidence of dyskinesias. This post hoc analysis investigated whether the dyskinesia‐sparing benefit of ropinirole is lost when levodopa is added to the regimen and evaluated other risk factors for developing dyskinesias. Patients receiving levodopa had a significantly higher risk of dyskinesias than those taking ropinirole monotherapy (hazard ratio [HR], 6.67; 95% confidence interval [CI], 3.23–14.29; P < 0.001). When patients randomized to ropinirole were treated with supplementary levodopa, the development of dyskinesias was not significantly different from that in those receiving levodopa from the start (HR, 0.80; 95% CI, 0.48–1.33; P = 0.39). However, the onset of dyskinesias was delayed by around 3 years compared with levodopa monotherapy. Adjusted analyses taking into account baseline and on‐treatment factors that influenced use of supplementary levodopa or the development of dyskinesias produced similar results. In conclusion, the risk of developing dyskinesias during maintained initial ropinirole monotherapy is very low. Only once levodopa is added does the risk substantially change. Early use of ropinirole postpones the onset of dyskinesias, but these benefits decline when levodopa therapy is started, with no evidence of a subsequent rapid “catch‐up” or a persisting preventive effect. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.20988
Affiliations:
- Belgique, Canada, France, Israël, Royaume-Uni
- Angleterre, Grand Londres, Midi-Pyrénées, Midlands de l'Ouest, Occitanie (région administrative), Ontario, Province d'Anvers, Région flamande
- Anvers, Birmingham, Londres, Toronto, Toulouse
- Université d'Anvers, Université de Birmingham, Université de Toronto
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000F89
- to stream Istex, to step Curation: 000F89
- to stream Istex, to step Checkpoint: 000B95
- to stream Main, to step Merge: 002B39
- to stream PascalFrancis, to step Corpus: 000788
- to stream PascalFrancis, to step Curation: 000532
- to stream PascalFrancis, to step Checkpoint: 000738
- to stream Main, to step Merge: 002C36
- to stream Main, to step Curation: 002852
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Development of dyskinesias in a 5‐year trial of ropinirole and L‐dopa</title>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
</author>
<author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name>
</author>
<author><name sortKey="Korczyn, Amos D" sort="Korczyn, Amos D" uniqKey="Korczyn A" first="Amos D." last="Korczyn">Amos D. Korczyn</name>
</author>
<author><name sortKey="De Deyn, Peter P" sort="De Deyn, Peter P" uniqKey="De Deyn P" first="Peter P." last="De Deyn">Peter P. De Deyn</name>
</author>
<author><name sortKey="Clarke, Carl E" sort="Clarke, Carl E" uniqKey="Clarke C" first="Carl E." last="Clarke">Carl E. Clarke</name>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
</author>
<author><name sortKey="Abdalla, Mona" sort="Abdalla, Mona" uniqKey="Abdalla M" first="Mona" last="Abdalla">Mona Abdalla</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:BB8195542AFAD4DEAA1B2B80E3E692FA9AD193D5</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/mds.20988</idno>
<idno type="url">https://api-v5.istex.fr/document/BB8195542AFAD4DEAA1B2B80E3E692FA9AD193D5/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">000F89</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000F89</idno>
<idno type="wicri:Area/Istex/Curation">000F89</idno>
<idno type="wicri:Area/Istex/Checkpoint">000B95</idno>
<idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000B95</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Rascol O:development:of:dyskinesias</idno>
<idno type="wicri:Area/Main/Merge">002B39</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:07-0021709</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000788</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000532</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000738</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000738</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Rascol O:development:of:dyskinesias</idno>
<idno type="wicri:Area/Main/Merge">002C36</idno>
<idno type="wicri:Area/Main/Curation">002852</idno>
<idno type="wicri:Area/Main/Exploration">002852</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Development of dyskinesias in a 5‐year trial of ropinirole and L‐dopa</title>
<author><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
<affiliation wicri:level="3"><country xml:lang="fr">France</country>
<wicri:regionArea>Clinical Investigation Centre, Department of Pharmacology and INSERM U455, Toulouse Hospital, Toulouse</wicri:regionArea>
<placeName><region type="region">Occitanie (région administrative)</region>
<region type="old region">Midi-Pyrénées</region>
<settlement type="city">Toulouse</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><country xml:lang="fr">France</country>
<wicri:regionArea>Faculty of Medicine, Department of Clinical Pharmacology, 37 allées Jules‐Guesde, 31000 Toulouse</wicri:regionArea>
<placeName><settlement type="city">Toulouse</settlement>
<region type="region" nuts="2">Occitanie (région administrative)</region>
<region type="old region" nuts="2">Midi-Pyrénées</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>Faculty of Medicine, Imperial College, Hammersmith Hospital, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Korczyn, Amos D" sort="Korczyn, Amos D" uniqKey="Korczyn A" first="Amos D." last="Korczyn">Amos D. Korczyn</name>
<affiliation wicri:level="1"><country xml:lang="fr">Israël</country>
<wicri:regionArea>Tel Aviv University Medical School, Tel Aviv</wicri:regionArea>
<wicri:noRegion>Tel Aviv</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="De Deyn, Peter P" sort="De Deyn, Peter P" uniqKey="De Deyn P" first="Peter P." last="De Deyn">Peter P. De Deyn</name>
<affiliation wicri:level="4"><country xml:lang="fr">Belgique</country>
<wicri:regionArea>Middelheim General Hospital, University of Antwerp, Antwerp</wicri:regionArea>
<orgName type="university">Université d'Anvers</orgName>
<placeName><settlement type="city">Anvers</settlement>
<region>Région flamande</region>
<region type="district" nuts="2">Province d'Anvers</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Clarke, Carl E" sort="Clarke, Carl E" uniqKey="Clarke C" first="Carl E." last="Clarke">Carl E. Clarke</name>
<affiliation wicri:level="4"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>University of Birmingham, Birmingham</wicri:regionArea>
<placeName><settlement type="city">Birmingham</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Midlands de l'Ouest</region>
<settlement type="city">Birmingham</settlement>
</placeName>
<orgName type="university">Université de Birmingham</orgName>
</affiliation>
</author>
<author><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
<affiliation wicri:level="4"><country xml:lang="fr">Canada</country>
<wicri:regionArea>Department of Medicine (Neurology) University of Toronto, Toronto</wicri:regionArea>
<orgName type="university">Université de Toronto</orgName>
<placeName><settlement type="city">Toronto</settlement>
<region type="state">Ontario</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Abdalla, Mona" sort="Abdalla, Mona" uniqKey="Abdalla M" first="Mona" last="Abdalla">Mona Abdalla</name>
<affiliation wicri:level="3"><country xml:lang="fr">Royaume-Uni</country>
<wicri:regionArea>London School of Hygiene and Tropical Medicine, London</wicri:regionArea>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="sub">Official Journal of the Movement Disorder Society</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-11">2006-11</date>
<biblScope unit="volume">21</biblScope>
<biblScope unit="issue">11</biblScope>
<biblScope unit="page" from="1844">1844</biblScope>
<biblScope unit="page" to="1850">1850</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">BB8195542AFAD4DEAA1B2B80E3E692FA9AD193D5</idno>
<idno type="DOI">10.1002/mds.20988</idno>
<idno type="ArticleID">MDS20988</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dyskinesia</term>
<term>Levodopa</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
<term>Parkinson's disease</term>
<term>Ropinirole</term>
<term>dyskinesia</term>
<term>levodopa</term>
<term>ropinirole</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dyskinésie</term>
<term>Lévodopa</term>
<term>Parkinson maladie</term>
<term>Ropinirole</term>
<term>Système nerveux pathologie</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">A 5‐year trial of ropinirole and levodopa in early Parkinson's disease showed that ropinirole is associated with reduced incidence of dyskinesias. This post hoc analysis investigated whether the dyskinesia‐sparing benefit of ropinirole is lost when levodopa is added to the regimen and evaluated other risk factors for developing dyskinesias. Patients receiving levodopa had a significantly higher risk of dyskinesias than those taking ropinirole monotherapy (hazard ratio [HR], 6.67; 95% confidence interval [CI], 3.23–14.29; P < 0.001). When patients randomized to ropinirole were treated with supplementary levodopa, the development of dyskinesias was not significantly different from that in those receiving levodopa from the start (HR, 0.80; 95% CI, 0.48–1.33; P = 0.39). However, the onset of dyskinesias was delayed by around 3 years compared with levodopa monotherapy. Adjusted analyses taking into account baseline and on‐treatment factors that influenced use of supplementary levodopa or the development of dyskinesias produced similar results. In conclusion, the risk of developing dyskinesias during maintained initial ropinirole monotherapy is very low. Only once levodopa is added does the risk substantially change. Early use of ropinirole postpones the onset of dyskinesias, but these benefits decline when levodopa therapy is started, with no evidence of a subsequent rapid “catch‐up” or a persisting preventive effect. © 2006 Movement Disorder Society</div>
</front>
</TEI>
<affiliations><list><country><li>Belgique</li>
<li>Canada</li>
<li>France</li>
<li>Israël</li>
<li>Royaume-Uni</li>
</country>
<region><li>Angleterre</li>
<li>Grand Londres</li>
<li>Midi-Pyrénées</li>
<li>Midlands de l'Ouest</li>
<li>Occitanie (région administrative)</li>
<li>Ontario</li>
<li>Province d'Anvers</li>
<li>Région flamande</li>
</region>
<settlement><li>Anvers</li>
<li>Birmingham</li>
<li>Londres</li>
<li>Toronto</li>
<li>Toulouse</li>
</settlement>
<orgName><li>Université d'Anvers</li>
<li>Université de Birmingham</li>
<li>Université de Toronto</li>
</orgName>
</list>
<tree><country name="France"><region name="Occitanie (région administrative)"><name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
</region>
<name sortKey="Rascol, Olivier" sort="Rascol, Olivier" uniqKey="Rascol O" first="Olivier" last="Rascol">Olivier Rascol</name>
</country>
<country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Brooks, David J" sort="Brooks, David J" uniqKey="Brooks D" first="David J." last="Brooks">David J. Brooks</name>
</region>
<name sortKey="Abdalla, Mona" sort="Abdalla, Mona" uniqKey="Abdalla M" first="Mona" last="Abdalla">Mona Abdalla</name>
<name sortKey="Clarke, Carl E" sort="Clarke, Carl E" uniqKey="Clarke C" first="Carl E." last="Clarke">Carl E. Clarke</name>
</country>
<country name="Israël"><noRegion><name sortKey="Korczyn, Amos D" sort="Korczyn, Amos D" uniqKey="Korczyn A" first="Amos D." last="Korczyn">Amos D. Korczyn</name>
</noRegion>
</country>
<country name="Belgique"><region name="Région flamande"><name sortKey="De Deyn, Peter P" sort="De Deyn, Peter P" uniqKey="De Deyn P" first="Peter P." last="De Deyn">Peter P. De Deyn</name>
</region>
</country>
<country name="Canada"><region name="Ontario"><name sortKey="Lang, Anthony E" sort="Lang, Anthony E" uniqKey="Lang A" first="Anthony E." last="Lang">Anthony E. Lang</name>
</region>
</country>
</tree>
</affiliations>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002852 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002852 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Canada |area= ParkinsonCanadaV1 |flux= Main |étape= Exploration |type= RBID |clé= ISTEX:BB8195542AFAD4DEAA1B2B80E3E692FA9AD193D5 |texte= Development of dyskinesias in a 5‐year trial of ropinirole and L‐dopa }}
This area was generated with Dilib version V0.6.29. |